Allied Market Research
Loading...
0
New
New
2021
Influenza Vaccine Market

Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Technology (Egg-based, and Cell culture), Age Group (Pediatric, and Adult), and Route of Administration (Injection, and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2021–2030

A01118
Pages: 217
Aug 2021 | 17399 Views
   
Author(s) : Vishal Bhardwaj, Ajinkya Alhat, Shubham Choudante , Omkar Sumant
Tables: 136
Charts: 44
  • Formats*:

  • SIngle User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • IComes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Influenza Vaccine Market

Request Now !

The global influenza vaccine market size was valued at $5024.60 million in 2020, and is projected to reach $10,127.0 million by 2030, registering a CAGR of 7.20% from 2021 to 2030. The viral infection which occurs due to flu in the respiratory system is called influenza. Influenza virus travels through respiratory droplets and it is contagious. It can also spread from one person to another while talking or due to physical contact. The influenza virus circulates continuously, causing regional epidemics and outbreaks which leads to thousands of deaths. Changing character of the virus is compelling an annual change in the vaccine strain to match the influenza virus strain. Healthcare organizations all over the world like Centers for Disease Control and Prevention (CDC) have suggested vaccines like baloxavir marboxil (Xofluza) for the treatment of influenza have recommended certain influenza vaccines such as baloxavir marboxil (Xofluza) to treat the symptoms in patients.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global influenza vaccine market. The number of population effected with COVID-19 virus increases, surge the demand for influenza vaccine. The influenza vaccine will not prevent COVID-19, but will decrease the illness, death and hospitalization. According to European Congress of Clinical Microbiology & infectious diseases (ECCMID), in 2021, it was reported that around 75,000 COVID-19 patient having shot of influenza vaccine are less prone to sepsis, stroke and deep vein thrombosis. As per the same source, in 2021, it was observed that flu vaccine may offer protection against COVID-19 virus. The patient suffering from COVID-19, and vaccinated with influenza vaccine are also less likely to admitted in intensive care unit. Subsequently, this leads to increase in demand for influenza vaccine.

The vaccines used for influenza are made up of three different influenza viruses like influenza type A with H3N2 virus strain, influenza type A with H1N1 virus strain, and influenza type B virus strain. Increase in prevalence of influenza epidemics and seasonal outbreaks is likely to expand the product sales during the projected period.

Influenza-Vaccine-market

Get more information on this report : Request Sample Pages

Increase in government support and surveillance regarding vaccination against influenza on the national and global levels to monitor the supply, distribution, and administration of flu vaccines is one of the crucial factors driving the market growth. Moreover, increase in investment by leading market players across the globe and rise in government funding have facilitated the launch of therapeutically effective vaccines drive the influenza vaccine market growth.

The immunization camps and programs conducted by various healthcare organizations have been affected due to the coronavirus pandemic. Having said that, the rates of the vaccination for flu has reached its peak in the pandemic due to a push by various healthcare operatives and government who are providing free vaccination to the citizens. Awareness has also raised amongst the populations due to the fear of flu and COVID-19.

Influenza Vaccine Market
By Vaccine Type

Your browser does not support the canvas element.

Quadrivalent segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Novel vaccine development is a huge process that generally takes about 10-15 years to develop and establish its safety and efficacy. Regulatory requirements for clinical trials vary in countries, which may delay the development of vaccines which limit the growth of the market.

Many companies like Sanofi, Emergent BioSolutions Inc., and F. Hoffmann-La Roche Ltd, are also helping in the distribution. On the other hand, many countries are facing undersupplies and delay in the approvals of vaccines and availability of vaccines due to the strict regulations during the clinical trials extending the timelines of vaccines delivery.

Influenza Vaccine Market
By Technology

Your browser does not support the canvas element.

Egg-Based segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Global Influenza Vaccine Market Segmentation

The influenza vaccine market is segmented into vaccine type, technology, age group, route of administration and region. By vaccine type, it is divided into quadrivalent and trivalent. By technology, it is classified into egg-based and cell-based. By age group, it is divided into pediatric and adult. By route of administration, it is categorized into injection and nasal spray. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Segment review

By vaccine type, it is divided into quadrivalent and trivalent. The quadrivalent type segment was the major revenue contributor in 2020, owing to its ability to immunize four influenza virus strains (two A subtypes and two B subtypes — H1N1 and H3N2 and Victoria and Yamagata, respectively). By technology, it is classified into egg-based and cell-based. 

Influenza Vaccine Market
By Age Group

Your browser does not support the canvas element.

Adult segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

The egg-based technology segment dominates the technology segment as it is most commonly used in production of both inactivated and live-attenuated vaccines. By age group, it is bifurcated into pediatric and adult. The adult age group segment was the highest contributor in the influenza vaccine market in 2020 and is expected to remain dominant during the forecast period, owing to higher risks of developing serious complications from influenza due to weaker immune response.  

North America accounted for the largest influenza vaccine market share in 2020 and is expected to retain its dominance throughout the forecast period. This is attributed to the increased prevalence of influenza in the region, increase in government focus on immunization programs, emergence of new vaccines, and growth in technological advancements for vaccine administration. However, Middle East and Africa is expected to emerge as a lucrative area with maximum growth potential, due to the increase in awareness program, improvement in healthcare facilities, available disposable income, and rapid development of economic conditions.

Influenza Vaccine Market
By Route of Administration

Your browser does not support the canvas element.

Injection segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

Some of the key players operating in the influenza vaccine market are AstraZeneca plc., Biodiem, CSL Limited, Emergent BioSolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., GlaxoSmithKline plc, Merck & Co. Inc. (Merck Sharp & Dohme Corp.), Novartis AG, Pfizer, Inc., Sanofi Pasteur SA, and Sinovac Biotech Ltd. 

Influenza Vaccine Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the global influenza vaccine market to identify the prevailing opportunities.
  • This study presents the competitive landscape of the global influenza vaccine market to predict the competitive environment across geographies.
  • Comprehensive analysis of factors that drive and restrict the influenza vaccine market growth is provided.
  • Region- & country-wise analysis is provided to understand the influenza vaccine market trends and dynamics

Key Market Segments

By Vaccine Type

  • Quadrivalent
  • Trivalent

By Type

  • Seasonal
  • Pandemic

By Technology

  • Egg-based
  • Cell-based

By Age Group

  • Pediatric
  • Adult 

By Route Of Administration

  • Injection
  • Nasal Spray

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
    • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Rest of Middle East and Africa

Key Market Players 

  • Astrazeneca Plc (Astrazeneca)
  • Biodiem
  • Csl Limited (Seqirus GmbH)
  • Emergent Biosolutions
  • F. Hoffmann-La Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • Glaxosmithkline Plc
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Novartis Ag
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.
 

CHAPTER 1:INTRODUCTION

1.1.Executive summary Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top Player Positioning
3.2.2.Top investment pockets
3.2.3.Top winning strategies

3.3.Porter's five force analysis
3.4.Market dynamics

3.4.1.Drivers

3.4.1.1.High prevalence of influenza
3.4.1.2.Increase in government focus on immunization programs
3.4.1.3.Emerging vaccines
3.4.1.4.Technological progress in vaccine administration

3.4.2.Restraints

3.4.2.1.Longer timelines and implementation of stringent regulations
3.4.2.2.High costs associated with the development of vaccines

3.4.3.Opportunity

3.4.3.1.High growth prospects in emerging markets

3.5.IMPACT ANALYSIS OF COVID-19 ON INFLUENZA VACCINE MARKET

CHAPTER 4:INFLUENZA VACCINE MARKET, BY VACCINE TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Quadrivalent

4.2.1.Key market trends and opportunities
4.2.2.Market size and forecast
4.2.3.Market analysis, by country

4.3.Trivalent

4.3.1.Key market trends and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

CHAPTER 5:INFLUENZA VACCINE MARKET, BY TECHNOLOGY

5.1.Overview

5.1.1.Market size and forecast

5.2.Egg-based

5.2.1.Market size and forecast
5.2.2.Market analysis, by country

5.3.Cell-based

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:INFLUENZA VACCINE MARKET, BY AGE GROUP

6.1.Overview

6.1.1.Market size and forecast

6.2.Pediatric

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Adult

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

CHAPTER 7:INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION

7.1.Overview

7.1.1.Market size and forecast

7.2.Injection

7.2.1.Market size and forecast
7.2.2.Market analysis, by country

7.3.Nasal spray

7.3.1.Market size and forecast
7.3.2.Market analysis, by country

CHAPTER 8:GLOBAL INFLUENZA VACCINE MARKET, BY REGION

8.1.Overview

8.1.1.Market size and forecast

8.2.North America

8.2.1.Key market trends and opportunities
8.2.2.Market size and forecast, by vaccine type
8.2.3.Market size and forecast, by technology
8.2.4.Market size and forecast, by age group
8.2.5.Market size and forecast, by route of administration
8.2.6.Market size and forecast, by country

8.2.6.1.U.S. market size and forecast, by vaccine type
8.2.6.2.U.S. market size and forecast, by technology
8.2.6.3.U.S. market size and forecast, by age group
8.2.6.4.U.S. market size and forecast, by route of administration
8.2.6.5.Canada market size and forecast, by vaccine type
8.2.6.6.Canada market size and forecast, by technology
8.2.6.7.Canada market size and forecast, by age group
8.2.6.8.Canada market size and forecast, by route of administration
8.2.6.9.Mexico market size and forecast, by vaccine type
8.2.6.10.Mexico market size and forecast, by technology
8.2.6.11.Mexico market size and forecast, by age group
8.2.6.12.Mexico market size and forecast, by route of administration

8.3.Europe

8.3.1.Key market trends and opportunities
8.3.2.Market size and forecast, by vaccine type
8.3.3.Market size and forecast, by technology
8.3.4.Market size and forecast, by age group
8.3.5.Market size and forecast, by route of administration
8.3.6.Market size and forecast, by country

8.3.6.1.Germany market size and forecast, by vaccine type
8.3.6.2.Germany market size and forecast, by technology
8.3.6.3.Germany market size and forecast, by age group
8.3.6.4.Germany market size and forecast, by route of administration
8.3.6.5.France market size and forecast, by vaccine type
8.3.6.6.France market size and forecast, by technology
8.3.6.7.France market size and forecast, by age group
8.3.6.8.France market size and forecast, by route of administration
8.3.6.9.UK market size and forecast, by vaccine type
8.3.6.10.UK market size and forecast, by technology
8.3.6.11.UK market size and forecast, by age group
8.3.6.12.UK market size and forecast, by route of administration
8.3.6.13.Italy market size and forecast, by vaccine type
8.3.6.14.Italy market size and forecast, by technology
8.3.6.15.Italy market size and forecast, by age group
8.3.6.16.Italy market size and forecast, by route of administration
8.3.6.17.Spain market size and forecast, by vaccine type
8.3.6.18.Spain market size and forecast, by technology
8.3.6.19.Spain market size and forecast, by age group
8.3.6.20.Spain market size and forecast, by route of administration
8.3.6.21.Rest of Europe market size and forecast, by vaccine type
8.3.6.22.Rest of Europe market size and forecast, by technology
8.3.6.23.Rest of Europe market size and forecast, by age group
8.3.6.24.Rest of Europe market size and forecast, by route of administration

8.4.Asia-Pacific

8.4.1.Key market trends and opportunities
8.4.2.Market size and forecast, by vaccine type
8.4.3.Market size and forecast, by technology
8.4.4.Market size and forecast, by age group
8.4.5.Market size and forecast, by route of administration

8.4.5.1.Japan market size and forecast, by vaccine type
8.4.5.2.Japan market size and forecast, by technology
8.4.5.3.Japan market size and forecast, by age group
8.4.5.4.Japan market size and forecast, by route of administration
8.4.5.5.China market size and forecast, by vaccine type
8.4.5.6.China market size and forecast, by technology
8.4.5.7.China market size and forecast, by age group
8.4.5.8.China market size and forecast, by route of administration
8.4.5.9.India market size and forecast, by vaccine type
8.4.5.10.India market size and forecast, by technology
8.4.5.11.India market size and forecast, by age group
8.4.5.12.India market size and forecast, by route of administration
8.4.5.13.Australia market size and forecast, by vaccine type
8.4.5.14.Australia market size and forecast, by technology
8.4.5.15.Australia market size and forecast, by age group
8.4.5.16.Australia market size and forecast, by route of administration
8.4.5.17.South Korea market size and forecast, by vaccine type
8.4.5.18.South Korea market size and forecast, by technology
8.4.5.19.South Korea market size and forecast, by age group
8.4.5.20.South Korea market size and forecast, by route of administration
8.4.5.21.Rest of Asia-Pacific market size and forecast, by vaccine type
8.4.5.22.Rest of Asia-Pacific market size and forecast, by technology
8.4.5.23.Rest of Asia-Pacific market size and forecast, by age group
8.4.5.24.Rest of Asia-Pacific market size and forecast, by route of administration

8.5.Latin America

8.5.1.Key market trends and opportunities
8.5.2.Market size and forecast, by vaccine type
8.5.3.Market size and forecast, by technology
8.5.4.Market size and forecast, by age group
8.5.5.Market size and forecast, by route of administration
8.5.6.Market size and forecast, by country

8.5.6.1.Brazil market size and forecast, by vaccine type
8.5.6.2.Brazil market size and forecast, by technology
8.5.6.3.Brazil market size and forecast, by age group
8.5.6.4.Brazil market size and forecast, by route of administration
8.5.6.5.Saudi Arabia market size and forecast, by vaccine type
8.5.6.6.Saudi Arabia market size and forecast, by technology
8.5.6.7.Saudi Arabia market size and forecast, by age group
8.5.6.8.Saudi Arabia market size and forecast, by route of administration
8.5.6.9.South Africa market size and forecast, by vaccine type
8.5.6.10.South Africa market size and forecast, by technology
8.5.6.11.South Africa market size and forecast, by age group
8.5.6.12.South Africa market size and forecast, by route of administration
8.5.6.13.Rest of LAMEA market size and forecast, by vaccine type
8.5.6.14.Rest of LAMEA market size and forecast, by technology
8.5.6.15.Rest of LAMEA market size and forecast, by age group
8.5.6.16.Rest of LAMEA market size and forecast, by route of administration

CHAPTER 9:COMPANY PROFILES

9.1.ASTRAZENECA PLC (ASTRAZENECA)

9.1.1.Company overview
9.1.2.Company snapshot
9.1.3.Operating business segments
9.1.4.Product portfolio
9.1.5.Business performance

9.2.BIODIEM LTD

9.2.1.Company overview
9.2.2.Company snapshot
9.2.3.Operating business segments
9.2.4.Product portfolio
Biodiem ltd. offers the following influenza vaccine:
9.2.5.Business performance
9.2.6.Key strategic moves and developments

9.3.CSL LIMITED (SEQIRUS GMBH)

9.3.1.Company overview
9.3.2.Company snapshot
9.3.3.Operating business segments
9.3.4.Product portfolio
9.3.5.Business performance
9.3.6.Key strategic moves and developments

9.4.EMERGENT BIOSOLUTIONS INC.

9.4.1.Company overview
9.4.2.Company snapshot
9.4.3.Operating business segments
9.4.4.Product portfolio
Emergent biosolutions inc. offers following influenza vaccines:
9.4.5.Business performance
9.4.6.Key strategic moves and developments

9.5.F. HOFFMANN-LA ROCHE LTD.

9.5.1.Company overview
9.5.2.Company snapshot
9.5.3.Operating business segments
9.5.4.Product portfolio
9.5.5.Business performance

9.6.GAMMA VACCINES PTY LTD.

9.6.1.Company overview
9.6.2.Company snapshot
9.6.3.Operating business segments
9.6.4.Product portfolio

9.7.GLAXOSMITHKLINE PLC

9.7.1.Company overview
9.7.2.Company snapshot
9.7.3.Operating business segments
9.7.4.Product portfolio
9.7.5.Business performance
9.7.6.Key strategic moves and developments

9.8.MERCK & CO., INC. (MERCK SHARP & DOHME CORP.)

9.8.1.Company overview
9.8.2.Company snapshot
9.8.3.Operating business segments
9.8.4.Product portfolio
9.8.5.Business performance

9.9.PFIZER, INC.

9.9.1.Company overview
9.9.2.Company snapshot
9.9.3.Operating business segments
9.9.4.Product portfolio
9.9.5.Business performance
9.9.6.Key strategic moves and developments

9.10.SANOFI

9.10.1.Company overview
9.10.2.Company snapshot
9.10.3.Operating business segments
9.10.4.Product portfolio
9.10.5.Business performance
9.10.6.Key strategic moves and developments

LIST OF TABLES

TABLE 01.GLOBAL INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 02.INFLUENZA VACCINE MARKET FOR QUADRIVALENT, BY REGION, 2018–2026, ($MILLION)
TABLE 03.INFLUENZA VACCINE MARKET FOR TRIVALENT, BY REGION, 2020–2030, ($MILLION)
TABLE 04.GLOBAL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030 ($MILLION)
TABLE 05.EGG-BASED INFLUENZA VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06.CELL-BASED INFLUENZA VACCINE MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07.GLOBAL INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 08.INFLUENZA VACCINE MARKET FOR PEDIATRIC AGE GROUP, BY REGION, 2020–2030, ($MILLION)
TABLE 09.INFLUENZA VACCINE MARKET FOR ADULT AGE GROUP, BY REGION, 2020–2030, ($MILLION)
TABLE 10.GLOBAL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 11.INFLUENZA VACCINE MARKET FOR INJECTION, BY REGION, 2020–2030, ($MILLION)
TABLE 12.INFLUENZA VACCINE MARKET FOR NASAL SPRAY, BY REGION, 2020–2030, ($MILLION)
TABLE 13.GLOBAL INFLUENZA VACCINE MARKET, BY REGION, 2020–2030, ($MILLION)
TABLE 14.NORTH AMERICA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 15.NORTH AMERICA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 16.NORTH AMERICA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 17.NORTH AMERICA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 18.NORTH AMERICA INFLUENZA VACCINE MARKET, BY COUNTRY, 2020–2030, ($MILLION)
TABLE 19.U.S. INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 20.U.S. INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 21.U.S. INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 22.U.S. INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 23.CANADA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 24.CANADA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 25.CANADA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 26.CANADA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 27.MEXICO INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 28.MEXICO INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 29.MEXICO INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 30.MEXICO INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 31.EUROPE INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 32.EUROPE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 33.EUROPE INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 34.EUROPE INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 35.EUROPE INFLUENZA VACCINE MARKET, BY COUNTRY, 2020–2030, ($MILLION)
TABLE 36.GERMANY INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 37.GERMANY INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 38.GERMANY INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 39.GERMANY INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 40.FRANCE INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 41.FRANCE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 42.FRANCE INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 43.FRANCE INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 44.UK INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 45.UK INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 46.UK INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 47.UK INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 48.ITALY INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 49.ITALY INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 50.ITALY INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 51.ITALY INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 52.SPAIN INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 53.SPAIN INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 54.SPAIN INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 55.SPAIN INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 56.REST OF EUROPE INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 57.REST OF EUROPE INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 58.REST OF EUROPE INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 59.REST OF EUROPE INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 60.ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 61.ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 62.ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 63.ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 64.JAPAN INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 65.JAPAN INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 66.JAPAN INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 67.JAPAN INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 68.CHINA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 69.CHINA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 70.CHINA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 71.CHINA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 72.INDIA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 73.INDIA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 74.INDIA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 75.INDIA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 76.AUSTRALIA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 77.AUSTRALIA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 78.AUSTRALIA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 79.AUSTRALIA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 80.SOUTH KOREA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 81.SOUTH KOREA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 82.SOUTH KOREA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 83.SOUTH KOREA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 84.REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 85.REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 86.REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 87.REST OF ASIA-PACIFIC INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 88.LAMEA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 89.LAMEA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 90.LAMEA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 91.LAMEA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 92.LAMEA INFLUENZA VACCINE MARKET, BY COUNTRY, 2020–2030, ($MILLION)
TABLE 93.BRAZIL INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 94.BRAZIL INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 95.BRAZIL INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 96.BRAZIL INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 97.SAUDI ARABIA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 98.SAUDI ARABIA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 99.SAUDI ARABIA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 100.SAUDI ARABIA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 101.SOUTH AFRICA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 102.SOUTH AFRICA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 103.SOUTH AFRICA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 104.SOUTH AFRICA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 105.REST OF LAMEA INFLUENZA VACCINE MARKET, BY VACCINE TYPE, 2020–2030, ($MILLION)
TABLE 106.REST OF LAMEA INFLUENZA VACCINE MARKET, BY TECHNOLOGY, 2020–2030, ($MILLION)
TABLE 107.REST OF MIDDLE EAST AND AFRICA INFLUENZA VACCINE MARKET, BY AGE GROUP, 2020–2030, ($MILLION)
TABLE 108.REST OF LAMEA INFLUENZA VACCINE MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030, ($MILLION)
TABLE 109.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 110.ASTRAZENECA: OPERATING SEGMENTS
TABLE 111.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 112.BIODIEM LTD: COMPANY SNAPSHOT
TABLE 113.BIODIEM: OPERATING SEGMENTS
TABLE 114.BIODIEM LTD: PRODUCT PORTFOLIO
TABLE 115.CSL LIMITED: COMPANY SNAPSHOT
TABLE 116.CSL LIMITED: OPERATING SEGMENTS
TABLE 117.CSL LIMITED: PRODUCT PORTFOLIO
TABLE 118.EMERGENT BIOSOLUTIONS INC: COMPANY SNAPSHOT
TABLE 119.EMERGENT BIOSOLUTIONS INC: PRODUCT PORTFOLIO
TABLE 120.ROCHE: COMPANY SNAPSHOT
TABLE 121.ROCHE: OPERATING SEGMENTS
TABLE 122.ROCHE: PRODUCT PORTFOLIO
TABLE 123.GAMMA VACCINES: COMPANY SNAPSHOT
TABLE 124.GAMMA VACCINES: OPERATING SEGMENTS
TABLE 125.GAMMA VACCINES: PRODUCT TYPE PORTFOLIO
TABLE 126.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
TABLE 127.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 128.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 129.MERCK.: COMPANY SNAPSHOT
TABLE 130.MERCK: OPERATING SEGMENTS
TABLE 131.MERCK: PRODUCT TYPE PORTFOLIO
TABLE 132.PFIZER INC: COMPANY SNAPSHOT
TABLE 133.PFIZER INC: PRODUCT TYPE PORTFOLIO
TABLE 134.SANOFI: COMPANY SNAPSHOT
TABLE 135.SANOFI: OPERATING SEGMENTS
TABLE 136.SANOFI: PRODUCT TYPE PORTFOLIO

LIST OF FIGURES

FIGURE 01.INFLUENZA VACCINE MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP INVESTMENT POCKETS
FIGURE 04.TOP WINNING STRATEGIES, BY YEAR, 2018–2020*
FIGURE 05.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2020* (%)
FIGURE 06.TOP WINNING STRATEGIES, BY COMPANY, 2018–2020*
FIGURE 07.LOW-MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08.HIGH BARGAINING POWER OF BUYERS
FIGURE 09.MODERATE THREAT OF NEW ENTRANTS
FIGURE 10.MODERATE THREAT OF SUBSTITUTION
FIGURE 11.HIGH INTENSITY OF COMPETITIVE RIVALRY
FIGURE 12.TOP IMPACTING FACTORS
FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR QUADRIVALENT, BY COUNTRY, 2020 & 2030 (%)
FIGURE 14.COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR TRIVALENT, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.COMPARATIVE SHARE ANALYSIS OF EGG-BASED INFLUENZA VACCINE, BY COUNTRY,  2020 & 2030 (%)
FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CELL CULTURE INFLUENZA VACCINE MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 17.COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE FOR PEDIATRIC AGE GROUP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 18.COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR ADULT AGE GROUP, BY COUNTRY, 2020 & 2030 (%)
FIGURE 19.COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE FOR INJECTION, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.COMPARATIVE SHARE ANALYSIS OF INFLUENZA VACCINE MARKET FOR NASAL SPRAY, BY COUNTRY, 2020 & 2030 (%)
FIGURE 21.ASTRAZENECA: REVENUE, 2018–2020 ($MILLION)
FIGURE 22.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 23.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 24.BIODIEM LTD: REVENUE, 2018–2020 ($MILLION)
FIGURE 25.CSL LIMITED: REVENUE, 2018–2020 ($MILLION)
FIGURE 26.CSL LIMITED: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 27.CSL LIMITED: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 28.EMERGENT BIOSOLUTIONS INC: REVENUE, 2018–2020 ($MILLION)
FIGURE 29.EMERGENT BIOSOLUTIONS INC: REVENUE SHARE BY PRODUCT, 2020 (%)
FIGURE 30.EMERGENT BIOSOLUTIONS INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 31.ROCHE: REVENUE, 2018–2020 ($MILLION)
FIGURE 32.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 33.ROCHE: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 34.GLAXOSMITHKLINE PLC: REVENUE, 2018–2020 ($MILLION)
FIGURE 35.GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 36.GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 37.MERCK: REVENUE, 2018–2020 ($MILLION)
FIGURE 38.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 39.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 40.PFIZER INC: REVENUE, 2018–2020 ($MILLION)
FIGURE 41.PFIZER INC: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 42.SANOFI: REVENUE, 2018–2020 ($MILLION)
FIGURE 43.SANOFI: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 44.SANOFI: REVENUE SHARE BY REGION, 2020 (%)

 
 

According to analyst perspective, the influenza vaccine industry holds the maximum potential, owing to the increase in R&D activities related to influenza vaccines, growth in immunization programs, and rise in the incidences of influenza globally which, in turn, are responsible to drive the market growth. Furthermore, significant technological advancements in the manufacturing technology of vaccines to improve efficacy and potency of vaccines along with increased investments by manufacturers to upgrade traditional vaccination production and delivery methods contribute to increased profit margins and enhanced operational efficiencies in the production of influenza vaccines, especially in the U.S. Novel vaccine development generally takes about 10-15 years to develop and establish its safety and efficacy which is a huge process and regulatory requirements for clinical trials vary in countries may delay in development of vaccines which is projected to limit the growth of the market.

PURCHASE OPTIONS

Start reading instantly ,This Report and over 13000+ thousand more Reports, Available with Avenue Library, T&C*

Call or Email us

U.S.-Canada
Toll-free :
+1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
FREQUENTLY ASKED QUESTIONS?
Our Report Looks Like This
 

A. The total market value of Influenza Vaccine Market is $5024.60 million in 2020

A. The forcast period for Influenza Vaccine Market is 2021 to 2031

A. The market value of Influenza Vaccine Market in 2030 is $10,127.00 million.

A. The base year is 2020 in Influenza Vaccine Market.

A. Astrazeneca, Biodem Ltd., CSL Ltd., Emergent Biosolutions Ltd., Roche held a high market postion owing to the strong geographical foothold in different regions.

A. Quadrivalent segment dominates the global market, this is attributed to the number of pharmaceutical companies producing this vaccines.

A. The major factor for the growth of Influenza Vaccine Market are high prevalence of influenza, increase in government focus on immunization programs, emerging vaccines and technological progress in vaccine administration.

A. Owing to rise in the number of vaccines available in the market along with government initiatives to improve the immunization programs. Furthermore, government initiatives and technological advancements toward flu is expected to propel the demand for Influenza Vaccine Market in the region.

A. Influenza commonly known as flu is a contagious respiratory infection or illness caused by influenza viruses. The influenza vaccine protects a person from getting the flu.

A. Flu vaccines are designed to protect against the influenza viruses that are predicted to be the most common during the upcoming season.

Allied Market Research Allied Market Research Allied Market Research
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Influenza Vaccine Market

Start reading instantly.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,712
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $4,125
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $6,168
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,929
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $10,663
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $ 699/mo
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Erythropoietin Drugs Market

Global Opportunity Analysis and Industry Forecast, 2021–2028

Published in May 2021

Download Sample

Protein Therapeutics Market

Global Opportunity Analysis and Industry Forecast, 2017-2023

Published in Nov 2017

Download Sample

Surgical Equipment Market

Global Opportunity Analysis and Industry Forecast, 2020-2027

Published in Jan 2021

Download Sample

Medical Implant Market

Global Opportunity Analysis and Industry Forecast, 2020–2027

Published in Nov 2020

Download Sample

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers